Digestaid – Artificial Intelligence Development SA

Porto, Portugal All Portugal companies → — Founded 2020

Imaging AI Specialist Specialty-Focused AI

Gastroenterology

Unfunded — unknown

Claim this company

Products

Deep Capsule

Digestaid - Artificial Intelligence Development SA

Gastroenterology AI

Deep Capsule is an AI software tool that assists in reviewing capsule endoscopy images by detecting and differentiating lesions, stratifying hemorrhagic potential, and highlighting clinically relevant frames for physician validation.

See all 1 product →

About Digestaid – Artificial Intelligence Development SA

Digestaid – Artificial Intelligence Development SA is a healthcare AI company focused on developing advanced deep learning solutions for the detection of digestive lesions. The company aims to revolutionize gastrointestinal practice by applying AI technologies across digestive and pancreatobiliary tracts, as well as functional tests. Their solutions are designed to overcome diagnostic limitations of current clinical and surgical methods, delivering faster, more accurate results, and supporting a more proficient clinical practice.

Digestaid offers a suite of deep learning algorithms for the detection, classification, and scoring of gastrointestinal lesions in various modalities, including capsule endoscopy and endoscopic video. They provide services such as automated capsule endoscopy analysis, real-time endoscopy AI modules for intra-procedural support, and software analysis for anorectal and high-resolution esophageal manometry recordings. The company emphasizes improving diagnostic performance, embracing innovation, and delivering cost-effective solutions to enhance patient care.

Focus Areas

AI for digestive endoscopy capsule endoscopy image analytics computer vision for live endoscopy clinical validation of diagnostic AI multicenter clinical dataset curation gastrointestinal motility data analysis high-performance medical image inference publication and scientific dissemination in gastroenterology gynecology pulmonology

Business Intelligence

Key Investors	unknown
Partnerships	Hospital Universitario Puerta de Hierro Majadahonda, Hospital Universitario de La Princesa, Medtronic, CINTESIS, Faculty of Medicine of the University of Porto, Faculty of Engineering of the University of Porto, Centro Hospitalar Universitário de São João (CHUSJ)
Acquisitions	unknown
Technology	Deep learning (Convolutional Neural Networks), real-time video inference, high-throughput inference optimization, computer vision for endoscopic imagery, signal processing for manometry, multicenter clinical dataset pipelines, automated classification using clinical scoring systems, cloud-native
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

AI for Digestive Endoscopy

Digestaid specializes in developing AI solutions to overcome diagnostic limitations in various digestive endoscopic methods, including capsule endoscopy and digital cholangioscopy. Their AI solutions aim to provide faster, more accurate results in clinical practice.

Capsule Endoscopy Image Analytics

They offer automated analysis services for capsule endoscopy videos, focusing on the detection and categorization of small-bowel and colonic lesions such as ulcers, erosions, vascular lesions, protuberant lesions, and blood. Their 'Deep Capsule' product identifies and differentiates normal mucosa and small-bowel lesions in previously acquired capsule endoscopy videos. 'GI Spy' identifies colon polyps and precursor lesions in capsule-colonoscopy videos and detects blood and mucosal lesions throughout the GI tract. 'IBD Smart' specifically detects ulcers and erosions in capsule endoscopy exams to support inflammatory bowel disease assessment.

Computer Vision for Live Endoscopy

Digestaid provides a real-time endoscopy AI module for intra-procedural support in various endoscopic modalities like cholangioscopy, EUS, anoscopy, and device-assisted enteroscopy. This module helps identify suspicious features and assists visual diagnosis. Their 'Deep Bowel' technology automatically detects protruding lesions, vascular lesions, ulcers, erosions, and blood in real-time during device-assisted enteroscopy.

Clinical Validation of Diagnostic AI

The company emphasizes clinical validation of their AI solutions. Their IBD Smart product, for example, has undergone multicenter validation, reporting 90.2% sensitivity and a 94.0% negative predictive value for detecting ulcers and erosions.

Multicenter Clinical Dataset Curation

Digestaid is involved in curating extensive, heterogeneous, and diverse datasets with over 10 million exams from world-renowned institutions.

Gastrointestinal Motility Data Analysis

They offer software analysis services for anorectal and high-resolution esophageal manometry recordings to extract relevant metrics and provide automated interpretations. Their 'Smart Esophagus' product provides AI-driven identification, classification, and reporting of esophageal motility patterns in high-resolution esophageal manometry according to Chicago Classification 4.0.

High-Performance Medical Image Inference

Digestaid focuses on high-performance medical image inference, utilizing technologies like convolutional neural networks (CNNs), deep learning for medical image analysis, real-time video inference, and high-throughput inference optimization.

Publication and Scientific Dissemination

The company actively engages in scientific dissemination, with over 500 publications in top-tier peer-reviewed journals and scientific meetings across gastroenterology, gynecology, and pulmonology.

Physician Tip

Digestaid's AI solutions are designed to enhance diagnostic performance by overcoming the limitations of conventional endoscopic methods, leading to faster and more accurate diagnoses. Their tools provide real-time support during procedures and offer automated analysis of complex imaging and motility data, aiming to reduce review time and improve diagnostic consistency. The physician remains in control, with AI providing insights and prioritized findings for validation. This can be particularly beneficial for detecting subtle lesions, assessing inflammatory activity, and standardizing interpretations of motility patterns. The company's focus on clinical validation and extensive datasets ensures the reliability and practical value of their AI in clinical use.

Digestaid builds and implements end-to-end AI solutions across multiple clinical and surgical fields. They partner with global medtech leaders, including Olympus and Jinshan, to integrate clinically meaningful AI into digestive healthcare. Their AI software is designed as an integrated platform extending across multiple clinical specialties and procedures, including GI & Hepatobiliary, Gynecology, Pulmonology, Surgical & Interventional, and Coloproctology. The software is physician-centered, visually precise, product-aware, and designed to evolve within a flexible interaction language.

At a glance

Founded 2020

HQ Porto, Portugal · Portugal

Team size 46

CEO Miguel Mascarenhas

Funding Unfunded — unknown

FDA clearances 2 (estimated)

Products 1

Products by Digestaid – Artificial Intelligence Development SA

1 product in the directory

Deep Capsule

Digestaid - Artificial Intelligence Development SA

Gastroenterology AI

What the Web Says

Digestaid - Artificial Intelligence Development SA is a company focused on developing AI-powered solutions for digestive healthcare, gynecology, and pulmonology. Their products aim to improve diagnostic accuracy and efficiency in identifying various lesions and conditions through the analysis of endoscopic and capsule endoscopy videos, as well as other physiological data. The company emphasizes its collaboration with leading care institutions and a team of medical doctors and engineers.

Overall: Positive

Strengths

Improved diagnostic accuracy for digestive lesions, including ulcers, erosions, and polyps.
Faster and more efficient analysis of complex medical data, such as capsule endoscopy videos and high-resolution esophageal manometry.
Physician-centered AI software designed to support clinical review and validation while keeping clinicians in control.
Potential to overcome diagnostic limitations of current clinical and surgical methods.
FDA 510(k) cleared and CE marked for some products, indicating regulatory compliance.
Collaboration with medical experts and institutions to develop and validate their technologies.

Limitations

Limited public reviews available on platforms like G2, Glassdoor, Capterra, or Reddit.
Specific employer or product reviews on major platforms are not readily available.
Regulatory status varies by product and market.
The company's global presence data is still being approved and verified.
No specific negative feedback or limitations were found in the provided search results regarding product performance or employer satisfaction.

Based on reviews from: DigestAID u2013 Digestive Artificial Intelligence Development Technologies, Digestaid - Artificial Intelligence Development SA | MTEC, Avenda Health: Products, FDA Status & Funding | Physician AI Tools, Artificial Intelligence-Enabled Medical Devices - FDA, About us - DigestAID, Smart Esophagus u2013 DigestAID, AI & Software - DigestAID, Products - DigestAID, Artificial intelligence accelerates diagnosis in the digestive system - INEGI, IBD Smart - DigestAID, Explainable AI in Digestive Healthcare and Gastrointestinal Endoscopy - MDPI, Artificial Intelligence Applied to Gastrointestinal Diagnostics: A Review - PMC - NIH, Working at Digital.ai: Employee Reviews | Indeed.com

Last updated: 2026-08-19

Videos

News, demos, and interviews about Digestaid – Artificial Intelligence Development SA.

Loading videos...

Videos load interactively. If none appear, search YouTube for Digestaid – Artificial Intelligence Development SA →

View all on YouTube

Press & Coverage

FDA

510(k) Premarket Notification - K250655

Digestaid - Artificial Intelligence Development SA received a 'Substantially Equivalent' decision from the FDA for their gastrointestinal capsule endoscopy analysis software device on March 12, 2026. This regulatory announcement indicates the device is cleared for marketing in the US.

2026-03

FDA

Artificial Intelligence-Enabled Medical Devices List

Digestaid - Artificial Intelligence Development SA is listed on the FDA's AI-Enabled Medical Device List, with a decision date of March 10, 2026, for a Gastroenterology-Urology device under product code QZF. This list provides transparency for AI-enabled medical devices authorized for marketing in the United States.

2026-03

Clinical and Translational Gastroenterology

Artificial Intelligence Driven Diagnosis of Motility Patterns in High Resolution Esophageal Manometry: A Multicentric Multidevice Study

Digestaid's 'Smart Esophagus' platform, which uses AI to enhance the detection and differentiation of esophageal motility patterns in high-resolution esophageal manometry, has a peer-reviewed publication in 'Clinical and Translational Gastroenterology' in 2025. The study provides clinical evidence for automatic motility pattern detection.

2025

Techniques in Coloproctology

Automatic detection of blood and other significant colonic lesions in colon capsule endoscopy: a multicentric study

A multicentric study on the automatic detection of blood and other significant colonic lesions in colon capsule endoscopy, developed by Digestaid, was published in 'Techniques in Coloproctology' in September 2021. This research highlights the company's advancements in AI for gastrointestinal diagnostics.

2021-09

Olympus (Official Press Release)

Olympus and DigestAID announce strategic partnership for first-in-field SaMD AI solutions

Olympus and Digestaid have announced a strategic partnership to develop first-in-field Software as a Medical Device (SaMD) AI solutions for digestive healthcare. This collaboration aims to integrate clinically meaningful AI into gastroenterological practice.

unknown

Jinshan (Partnership Announcement)

Jinshan and DigestAID: a unified vision for smarter GI diagnostics

Jinshan and Digestaid have announced a partnership focused on a unified vision for smarter GI diagnostics. This collaboration aims to advance AI solutions in gastrointestinal healthcare.

unknown

MTEC

Digestive Disease Week 2021

Digestaid presented four scientific communications on AI in capsule endoscopy at Digestive Disease Week 2021, covering topics like detection of ulcers, erosions, and blood in the gastrointestinal tract. Some of these works received oral communication and poster awards.

2021

MTEC

XX Reuniu00e3o Ibu00e9rica de Cu00e1psula Endoscu00f3pica 2022

Digestaid presented research on deep learning for automatic identification and differentiation of small bowel lesions at the XX Iberian Meeting of Capsule Endoscopy 2022, with one work recognized as the best oral communication.

2022

Frequently Asked Questions

What specific AI solutions does Digestaid offer for digestive endoscopy and capsule endoscopy image analytics?

Digestaid specializes in AI for digestive endoscopy, including computer vision for live endoscopy and advanced analytics for capsule endoscopy images. Our solutions aim to enhance diagnostic accuracy and efficiency by providing real-time insights and automated analysis of endoscopic data. We focus on identifying subtle abnormalities and improving the overall diagnostic workflow for gastroenterologists.

How does Digestaid clinically validate its diagnostic AI algorithms, and what is your approach to multicenter clinical dataset curation?

Digestaid prioritizes rigorous clinical validation of its diagnostic AI algorithms through extensive studies and collaborations with leading medical institutions. We employ a robust approach to multicenter clinical dataset curation, ensuring diverse and high-quality data for training and testing our AI models. This commitment to validation and data integrity ensures the reliability and generalizability of our AI solutions in real-world clinical settings.

Beyond endoscopy, does Digestaid's AI technology extend to other gastrointestinal areas like motility data analysis, or other medical specialties such as gynecology or pulmonology?

While our core expertise is in digestive endoscopy, Digestaid's AI technology does extend to gastrointestinal motility data analysis, offering insights into complex GI disorders. Currently, our primary focus remains within gastroenterology. We do not currently have products or active development in gynecology or pulmonology, but our underlying AI platform has the potential for broader applications in medical image analysis and data interpretation.

What is Digestaid's pricing model for its AI solutions, and what kind of technical support and training can healthcare providers expect?

Digestaid offers flexible pricing models tailored to the specific needs and scale of healthcare providers, which can include subscription-based licensing or per-procedure fees. We provide comprehensive technical support, including dedicated account management, 24/7 assistance, and regular software updates. Additionally, we offer extensive training programs for physicians and technical staff to ensure seamless integration and optimal utilization of our AI platforms.

How does Digestaid ensure compliance with medical device regulations and data privacy standards (e.g., GDPR, HIPAA) for its AI products?

Digestaid is committed to upholding the highest standards of compliance with medical device regulations globally, including CE marking and FDA clearance processes where applicable. We adhere strictly to data privacy regulations such as GDPR and HIPAA, implementing robust security measures and anonymization protocols to protect patient data. Our commitment to compliance ensures the safe and ethical deployment of our AI solutions in clinical practice.

What is the current stability of Digestaid as a company, and what are your plans for future partnerships and scientific dissemination in gastroenterology?

Digestaid is a stable and growing company with strong investor backing and a clear vision for the future of AI in gastroenterology. We actively seek strategic partnerships with academic institutions, medical device companies, and healthcare providers to further advance our technology and expand our reach. We are also dedicated to scientific dissemination, regularly publishing our research in peer-reviewed gastroenterology journals and presenting at international conferences to share our advancements with the medical community.

Related Companies

Suggest an Edit →